Once-yearly zoledronic acid benefits men with osteoporosis

Once-yearly zoledronic acid benefits men with osteoporosis
For men with osteoporosis, a once-yearly infusion with zoledronic acid is associated with fewer vertebral fractures and improved bone health compared with placebo, according to a study published in the Nov. 1 issue of the New England Journal of Medicine.

(HealthDay)—For men with osteoporosis, a once-yearly infusion with zoledronic acid is associated with fewer vertebral fractures and improved bone health compared with placebo, according to a study published in the Nov. 1 issue of the New England Journal of Medicine.

Steven Boonen, M.D., Ph.D., from the Katholieke Universiteit Leuven in Belgium, and colleagues investigated the effect of zoledronic acid on in a multicenter, randomized trial involving 1,199 men with osteoporosis. Participants, aged 50 to 85 years, were randomly allocated to receive an intravenous infusion of either zoledronic acid or placebo at baseline and at 12 months. All participants received calcium and vitamin D each day and were followed for 24 months.

The researchers found that, over the 24-month period, the rate of any new morphometric vertebral fractures was 1.6 percent in the zoledronic acid group and 4.9 percent in the (relative risk, 0.33; P = 0.002). Men who received zoledronic acid had significantly fewer moderate-to-severe vertebral fractures and significantly less height loss compared with those receiving placebo. Fewer men in the zoledronic acid group had clinical vertebral or non-vertebral fractures, although due to the small number of fractures, this difference did not reach significance. Men who received zoledronic acid had higher and lower levels of bone-turnover markers.

"In conclusion, our prospective study that assessed fractures as the primary end point in men with osteoporosis showed that, over a two-year period, a once-yearly infusion of zoledronic acid at a dose of 5 mg was associated with a significant decrease in the risk of new ," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Novartis, which funded the study and manufactures zoledronic acid.

More information: Full Text (subscription or payment may be required)

Related Stories

Once-a-year drug reduces fractures from osteoporosis

date May 02, 2007

A treatment for osteoporosis delivered once a year is as effective as current monthly or weekly osteoporosis regimens at reducing the incidence of bone fractures, according to a new study led by a UCSF research team.

Recommended for you

Brittle bone disease: Drug research offers hope

date 1 hour ago

New research at the University of Michigan offers evidence that a drug being developed to treat osteoporosis may also be useful for treating osteogenesis imperfecta or brittle bone disease, a rare but potentially debilitating ...

Why gastrointestinal disorders afflict women more often

date 6 hours ago

Women are more likely to have irritable bowel syndrome and other gastrointestinal (GI) disorders than men are. Although this could be because men and women handle the condition differently— "toughing it out" versus getting ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.